Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

In Vitro Model of a Fibrosa Layer of a Heart Valve
Jana, Soumen , Simari, Robert D., Lerman, Amir

ACS Applied Materials & Interfaces | August 21, 2015 | Volume: 7 | Issue: 36 | Pages: 20012-20020

10.1021/acsami.5b04805 | PMID 26295833 Get It

Switching to a Pediatric Dose O-Arm Protocol in Spine Surgery Significantly Reduced Patient Radiation Exposure
Su, Alvin W.Y. , Luo, T. David , McIntosh, Amy L. , Schueler, Beth A. , Winkler, Jennifer, Stans, Anthony A. , Larson, A. Noelle , Su, Alvin W, Larson, A Noelle

Journal of Pediatric Orthopaedics | August 21, 2015 | Volume: 36 | Issue: 6 | Pages: 621-626

10.1097/bpo.0000000000000504 | PMID 26296221 Get It

Background: Intraoperative computed tomography and image-guided navigation improve the accuracy of screw placement. Radiation exposure to the patient remains a primary drawback. The objective of the present study was to compare the total intraoperative radiation dose and assess the resultant image quality for O-arm-assisted pedicle screw insertion, among 3 protocols: default (manufacturer recommended), institutional (reduced dose utilized in our institution), and pediatric (new protocol with lowest dose). Methods: Thirty-seven consecutive patients under the age of 18 years underwent posterior instrumentation of the spine and underwent an intraoperative O-arm scan. Techniques (kV and mAs) for default and institutional dose settings were manually adjusted based on spinal level and body weight. Pediatric dose techniques were 80 kV/80 mAs with no adjustment for level or weight. The number of scans repeated because of inadequate imaging was assessed, and the mean estimated effective dose between the 3 protocols was compared. Results: Sixty-eight scans were performed in 37 consecutive patients with mean age of 14 years and mean weight of 55 kg. For reference, the effective radiation dose of a chest x-ray is approximately 0.10 mSv. Use of the default protocol resulted in higher mean effective dose per scan of 4.65 mSv, whereas institutional protocol resulted in 2.37 mSv. The pediatric protocol reduced the mean dose to 0.65 mSv. The total effective dose per surgery was: 1.17 mSv (pediatric), 3.83 mSv (institutional), and 12.79 mSv (default) (P<0.0001 each). All scans lead to satisfactory image quality except in 1 patient >100 kg with stainless steel implants. There were no neurological or other implant-related complications. The pediatric protocol resulted in satisfactory image quality with the lowest total radiation dose, only 1/10 of that of the default protocol. Conclusions: We successfully switched to a pediatric low-dose O-arm protocol in clinical practice, reducing the dose to <1/4 of the mean annual natural background radiation. This may allow use of intraoperative computed tomography and navigation for pedicle screw placement without excessive radiation exposure to young patients. Level of Evidence: Level III—retrospective comparative study.
Outcomes and Complications of Lead Removal: Can We Establish a Risk Stratification Schema for a Collaborative and Effective Approach?
Fu, Hai‐Xia , Huang, Xinmiao, Li, Zhong , Osborn, Michael J., Asirvatham, Samuel J. , Espinosa, Raúl E. , Brady, Peter A. , Lee, Hon-Chi , Greason, Kevin L. , Sohail, M. Rizwan , Acker, Nancy G., Hodge, David O. , Friedman, Paul A. , Cha, Yong‐Mei , Sohail, Rizwan M., Baddour, Larry M. , Asirvatham, Samuel J , Sohail, M Rizwan

Pacing and Clinical Electrophysiology | August 21, 2015 | Volume: 38 | Issue: 12 | Pages: 1439-1447

10.1111/pace.12736 | PMID 26293652 Get It

Abstract IA25: Targeting genetic heterogeneity in multiple myeloma through immune activation.
Chesi, Marta , Bergsagel, P. Leif

Clinical Cancer Research | August 21, 2015 | Volume: 21 | Issue: 17_Supplement | Pages: IA25-IA25

10.1158/1557-3265.hemmal14-ia25 Get It

Abstract Multiple myeloma (MM) cells are the malignant counterpart of post-germinal center (GC) long-lived PCs, characterized by strong BM dependence, somatic hypermutation (SHM) of immunoglobulin (Ig) genes, and isotype class switch recombination (CSR) resulting in absence of IgM expression in all but 1% of tumors. Virtually every case of MM is preceded by a pre-malignant PC tumor called monoclonal gammopathy of undetermined significance (MGUS) that, like MM, produces a typical M-spike by SPEP or free light chain in the urine. Translocations involving the immunoglobulin heavy chain (IgH) locus are present in at least half of MM cases and are thought to result from errors during the physiological process of CSR or SHM. These translocations result in dysregulated expression of an oncogene that is juxtaposed to the strong Ig enhancers. There are three recurrent primary IgH translocation groups in MM: CYCLIN D (11q13-CYCLIN D1; 12p13-CYCLIN D2; 6p25-CYCLIN D3) MAF (16q23-MAF; 20q12-MAFB; 8q24.3-MAFA; MMSET/(FGFR3)-4p16-(MMSET in all but also FGFR3 in 80% of these tumors. Multiple trisomies represent an alternative pathogenetic pathway. There is a consensus that chromosome content reflects at least two pathways of pathogenesis. Nearly half of MGUS and MM tumors are hyperdiploid (HRD), usually with extra copies of three or more specific chromosomes (3,5,7,9,11,15,19, 21). Strikingly, HRD tumors rarely (~10%) have a primary IgH translocation, whereas Non-hyperdiploid (NHRD) tumors usually (~70%) have an IgH translocation. Almost all cases of plasma cell neoplasm starting from the MGUS stage and independently on the chromosome content aberrantly express one or more of the CYCLIN D genes and it has been proposed that dysregulation of a CYCLIN D gene provides a unifying, early oncogenic event in MGUS and MM. Consistently, the dysregulation of CYCLIN D1 in mouse B cells is sufficient to induce a monoclonal gammopathy that does not progress to MM. Secondary oncogenic events drive MGUS and MM progression MYC dysregulation. There is increased expression of c-MYC in most newly diagnosed MM tumors compared to MGUS tumor. Recently, it was shown that sporadic activation of a MYC transgene (Vk*MYC) in GC B cells in an MGUS prone mouse strain led to the universal development of MM tumor. Hence, increased MYC expression may be responsible for progression from MGUS to MM. Complex translocations involving MYC appear to be secondary progression events that often do not involve Ig loci, but rather other super enhancers that are very active in plasma cells. They are rare or absent in MGUS, but recently identified in over 40% of untreated MM, and 90% of MM cell lines. Activating mutations of RAS and BRAF. The prevalence of activating NRAS or KRAS mutations is about 15-18% each in newly diagnosed and relapsed MM tumors, and recently, BRAF mutations were described in 4% of MM tumors. Expression of an activated of KRAS in mouse B cells is sufficient to induce a monoclonal gammopathy but it does not progress to MM. Not surprisingly, dysregulating pairs of CYCLIN D1, KRAS and/or MYC in mouse B cells accelerated the progression of MM. Activating mutations of NFkappaB pathway. Extrinsic ligands (APRIL and BAFF) produced by BM stromal cells provide critical survival signals to long-lived PCs by stimulating TACI, BCMA, and BAFF receptors to activate the NFKB pathways. Most MGUS and MM tumors highly express NFKB target genes, suggesting a continued role of extrinsic signaling in PC tumors and at least in part explaining the constant dependency of MM cells on the BM microenvironment. Activating mutations in positive regulators and inactivating mutations in negative regulators of the NFKB pathway have been identified in at least 20% of untreated MM tumors and ~50% of HMCLs, rendering the cells less dependent on ligand-mediated NFKB activation and most likely contributing to extra-medullary spread of the disease. Additional changes include monosomy 13 (DIS3, mir15/16, RB1), del17p (TP53), add1q (MCL1) and del1p (CDKN2C, FAM46C). While the role of these putative tumor suppressor/oncogene remain to be defined, we found that loss of one copy of miR15/16 cooperated with MYC to cause the progression of MM in mice, while loss of one copy of RB1 did not, implicating loss of miR15/16 as one driving force behind selection for monosomy 13 in human MM. High-risk MM is associated with intra-clonal tumor heterogeneity Recent evidence indicates that tumor heterogeneity is prevalent in MM, as in many other cancers, and that different subclones are present within the tumor population, characterized by distinct genetic mutations that contributed independently to the tumor progression. The degree of clonal heterogeneity is presumably related to the degree of genomic instability, and appears to correlate with the presence of high-risk genetics. Three patterns of relapse are seen following successful therapy. A third of the time the dominant clone at diagnosis predominates, unchanged, at relapse. A third of the time the diagnostic clone has acquired additional genetic changes at relapse. And a third of the time an ancestral clone to the one dominant at diagnosis emerges, lacking some of the genetic changes present in the diagnostic clone, and having acquired additional genetic changes. Activating the immune system to overcome tumor heterogeneity MM cells develop a malignant relationship with components of the innate immune system in the BM. Initially inflammatory macrophages support MM tumor development, but over time convert to an immunosuppressive M2 phenotype. This relationship can be disrupted by activating signaling downstream of TLR and TNFR receptors in macrophages through the use of IAP antagonists which target for destruction negative regulators of these pathways (cIAP1/2). In MM bearing mice with a mature (but not those with an immature) immune system this results in a complete response, with no evidence of a direct anti-tumor effect of IAP antagonists on the tumor cells at clinically relevant doses. This has led to a phase II clinical trial of IAP antagonists to activate the innate immune system in patients with MM. The treatment is associated with dramatic activation and mobilization of macrophages, with cytokine release and early evidence of anti-tumor effects. Conclusion Significant progress has been made is understanding the molecular pathogenesis and biology of MM. Oncogenic pathways can be activated through cell intrinsic or extrinsic mechanisms. Similar to other cancers, MM is characterized by multi-stage accumulation of genetic abnormalities deregulating different pathways. Much of this knowledge is already being utilized for diagnosis, prognosis and risk-stratification of patients. Importantly, from a clinical standpoint, this knowledge has led to development of novel therapeutic strategies, some of which are already in clinical use, and many others showing promise in pre-clinical and early clinical studies. Citation Format: Marta Chesi, P. Leif Bergsagel. Targeting genetic heterogeneity in multiple myeloma through immune activation. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr IA25.
Abstract B28: Co-occupancy of AML1-ETO and N-CoR defines a dominant phenotypic signature in leukemic cells.
Trombly, Daniel J., Padmanabhan, Srivatsan , Gordon, Jonathan A. R., Lian, Jane B. , Wijnen, André J. van , Stein, Janet L. , Whitfield, Troy W. , Zaidi, Sayyed K. , Stein, Gary S. , van Wijnen, Andre J

Clinical Cancer Research | August 21, 2015 | Volume: 21 | Issue: 17_Supplement | Pages: B28-B28

10.1158/1557-3265.hemmal14-b28 Get It

Abstract The t(8;21) chromosomal translocation produces AML1-ETO, an oncogenic fusion protein that compromises the function of AML1, a transcription factor critical for the myeloid cell differentiation. The differentiation arrest and self-renewal phenotypes of cells expressing AML1-ETO have been chiefly studied at the single gene level. In order to understand how the genome-wide occupancy of AML1-ETO and associated co-regulators contributes to the leukemic properties of Kasumi-1 cells, a model system for human t(8;21) leukemia, chromatin immunoprecipitation-sequencing (ChIP-seq) experiments were employed. Genome-wide DNA binding profiles for AML1 and AML1-ETO in Kasumi-1 cells showed that both proteins were enriched at introns and distal upstream regulatory regions, the latter implying that distal elements are likely important for target gene regulation. Importantly, A substantial fraction of AML1/AML1-ETO-p300 co-localization occurs near transcriptional start sites (TSSs) in promoter regions associated with transcriptionally active loci, as indicated by an observed enrichment of the H3K4me3 histone modification. A significant discovery of the current study is the co-localization of AML1/AML1-ETO with N-CoR on regions that are primarily distal to TSSs. Analyses of both gene expression data and gene ontology suggest that the AML1/AML1-ETO co-localization with N-CoR, more so than with p300, is associated with the leukemic phenotype of Kasumi-1 cells. De novo motif discovery reveals that PU.1 motifs are over-represented in regions co-occupied by AML1-ETO and N-CoR compared to other AML1-ETO bound regions. Our findings establish a novel and predominant AML leukemia signature characterized by occupancy of the AML1-ETO/N-CoR complex at genomic regions enriched in motifs for myeloid differentiation factors. We propose that this property is critical for maintenance of the leukemic phenotype. Citation Format: Daniel J. Trombly, Troy W. Whitfield, Srivatsan Padmanabhan, Jonathan A. Gordon, Jane B. Lian, Andre J. van Wijnen, Sayyed K. Zaidi, Janet L. Stein, Gary S. Stein. Co-occupancy of AML1-ETO and N-CoR defines a dominant phenotypic signature in leukemic cells. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr B28.
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
Joseph, Richard W. , Serie, Daniel, Parasramka, Mansi, Ho, Thai H. , Cheville, John C. , Frenkel, Eugene P., Parker, Alexander S. , Brugarolas, James , Kapur, Payal , Serie, Daniel J, Frenkel, Eugene, Ho, Thai , Brugarolas, James

Journal of Urology | August 20, 2015 | Volume: 195 | Issue: 1 | Pages: 180-187

10.1016/j.juro.2015.07.113 | PMID 26300218 Get It

The risk of iatrogenic pneumothorax after electromyography
Kassardjian, Charles D. , O’Gorman, Cullen , Sorenson, Eric J. , O'Gorman, Cullen M, O'gorman, Cullen M

Muscle & Nerve | August 20, 2015 | Volume: 53 | Issue: 4 | Pages: 518-521

10.1002/mus.24883 | PMID 26333600 Get It

ABSTRACTIntroductionPneumothorax is a potentially serious complication of electromyography (EMG). Data on the frequency of pneumothorax after EMG are lacking. The purpose of this study was to determine the frequency, timing, and risk factors for iatrogenic pneumothorax after EMG. Methods: Cases of pneumothorax after EMG were reviewed for clinical, electrophysiological, and radiological data. Results: Of 64,490 EMG studies, 7 patients had an association between the EMG and pneumothorax. All patients were symptomatic and presented within 24 hours of EMG. Sampling of serratus anterior and diaphragm was causative in 1 patient each. In 5 patients, multiple high‐risk muscles were sampled. The highest frequency of pneumothorax was observed with examination of serratus anterior (0.445%) and diaphragm (0.149%). Conclusions: The frequency of symptomatic iatrogenic pneumothorax after EMG appears to be low, and examinations of serratus anterior and diaphragm carry the highest risk. Electromyographers should be aware of the risk of pneumothorax and should counsel patients accordingly. Muscle Nerve 53: 518–521, 2016
National Survey and Community Advisory Board Development for a Bipolar Disorder Biobank
Frye, Mark A. , Doederlein, Allen, Koenig, Barbara A. , Nassan, Malik , Seymour, Lisa R. , Daniels, Allen S., McElroy, Susan L. , Biernacka, Joanna M.

Bipolar Disorders | August 20, 2015 | Volume: 17 | Issue: 6 | Pages: 598-605

10.1111/bdi.12322 | PMID 26291791 Get It

ObjectivesThe aim of the present study was to engage a national advocacy group and local stakeholders for guidance in developing a bipolar disorder biobank through a web‐based survey and a community advisory board.MethodsThe Depression and Bipolar Support Alliance and the Mayo Clinic Bipolar Biobank conducted a national web‐based survey inquiring about interest in participating in a biobank (i.e., giving DNA and clinical information). A community advisory board was convened to guide establishment of the biobank and identify key deliverables from the research project and for the community.ResultsAmong 385 survey respondents, funding source (87%), professional opinion (76%), mental health consumer opinion (79%), and return of research results (91%) were believed to be important for considering study participation. Significantly more patients were willing to participate in a biobank managed by a university or clinic (78.2%) than one managed by government (63.4%) or industry (58.2%; both p < 0.001). The nine‐member community advisory board expressed interest in research to help predict the likelihood of bipolar disorder developing in a child of an affected parent and which medications to avoid. The advisory board endorsed the use of a comprehension questionnaire to evaluate participants' understanding of the study (e.g., longevity of DNA specimens, right to remove samples, accessing medical records) as a means to strengthen the informed consent process.ConclusionsThese national survey and community advisory data support the merit of establishing a biobank to enable studies of disease risk, provided that health records and research results are adequately protected. The goals of earlier diagnosis and individualized treatment of bipolar disorder were endorsed.
van der Waals force-induced loading of proangiogenic nanoparticles on microbubbles for enhanced neovascularization
Chen, Jinrong , Lee, Min Kyung , Qin, Ellen C., Kong, Hyunjoon , Misra, Sanjay , Lee, Min Kyung, Misra, Sanjay, Kong, Hyunjoon , Misra, Sanjay

Nanoscale | August 20, 2015 | Volume: 7 | Issue: 40 | Pages: 17139-17147

10.1039/c5nr03399c | PMID 26422546 Get It

Nanoparticles emerged as carriers of promising diagnostic and therapeutic molecules due to their unique size, injectability, and potential to sustainably release molecular cargos.
Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy
Personett, Heather A. , Larson, Scott L., Frazee, Erin N., Nyberg, Scott L. , Zoghby, Ziad , El-Zoghby, Ziad M, Frazee, Erin N., El-Zoghby, Ziad

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 19, 2015 | Volume: 35 | Issue: 8 | Pages: No page available

10.1002/phar.1618 | PMID 26289310 Get It

Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein‐bound and water‐soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram‐negative infections. Use of an extended‐infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.